1. Home
  2. PVL vs NOTV Comparison

PVL vs NOTV Comparison

Compare PVL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.83

Market Cap

57.8M

Sector

Energy

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.76

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
NOTV
Founded
2011
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
29.9M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
PVL
NOTV
Price
$1.83
$0.76
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
75.3K
1.6M
Earning Date
01-01-0001
12-03-2025
Dividend Yield
20.11%
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$3,511,891.00
$513,024,000.00
Revenue This Year
N/A
$6.26
Revenue Next Year
N/A
$45.49
P/E Ratio
$27.95
N/A
Revenue Growth
11.77
4.54
52 Week Low
$1.30
$0.66
52 Week High
$2.04
$6.48

Technical Indicators

Market Signals
Indicator
PVL
NOTV
Relative Strength Index (RSI) 44.64 35.16
Support Level $1.83 $0.79
Resistance Level $1.90 $0.86
Average True Range (ATR) 0.05 0.07
MACD 0.00 0.01
Stochastic Oscillator 31.25 3.93

Price Performance

Historical Comparison
PVL
NOTV

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: